prasinezumab

^[1]^[2]

Contraindications

* antibody at center of scientific miscoduct investigation

papers cited on the web site of its developer, Prothena, are full of manipulated images^[2]

↑ ^1.0 ^1.1 ^1.2 Pagano G et al. Trial of prasinezumab in early-stage Parkinson's disease. N Engl J Med 2022 Aug 4;387:421. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35921451 https://www.nejm.org/doi/10.1056/NEJMoa2202867
Whone A. Monoclonal antibody therapy in Parkinson's disease - The end? N Engl J Med 2022 Aug 4;387:466. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35921458 https://www.nejm.org/doi/10.1056/NEJMe2207681
↑ ^2.0 ^2.1 Pillar C Picture imperfect. Scores of papers by Eliezer Masliah, prominent neuroscientist and top NIH official, fall under suspicion. Science Sept 26, 2024 https://www.science.org/content/article/research-misconduct-finding-neuroscientist-eliezer-masliah-papers-under-suspicion